Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Long-chain PUFAs in infant formula may boost cognitive abilities -- study.

This article was originally published in The Tan Sheet

Executive Summary

LCPUFA-ADDED INFANT FORMULA MAY IMPROVE COGNITIVE ABILITIES by developing and stimulating infants' problem-solving aptitude, according to a study in the Aug. 29 Lancet. The randomized trial of 44 infants, conducted by P. Willatts, PhD, et al., University of Dundee, U.K., found infant formula supplemented with long-chain polyunsaturated fatty acids to be beneficial for term infants and that the effects "seem to persist beyond the period of supplementation."

You may also be interested in...



Mead DHA/ARA-Fortified Infant Formula Slated For February Release

Mead Johnson Nutritionals' Enfamil LIPIL, an infant formula fortified with ARA and DHA fatty acid oils, will be priced in the U.S. at a 10%-15% premium to the line's Enfamil with Iron product, the firm said

Mead DHA/ARA-Fortified Infant Formula Slated For February Release

Mead Johnson Nutritionals' Enfamil LIPIL, an infant formula fortified with ARA and DHA fatty acid oils, will be priced in the U.S. at a 10%-15% premium to the line's Enfamil with Iron product, the firm said

Mead DHA/ARA-Fortified Infant Formula Slated For February Release

Mead Johnson Nutritionals' Enfamil LIPIL, an infant formula fortified with ARA and DHA fatty acid oils, will be priced in the U.S. at a 10%-15% premium to the line's Enfamil with Iron product, the firm said

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088820

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel